Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2023 Earnings Call Transcript

Gilmore O’Neill: I think another way, Joon, to actually characterize this because some of the prevalence is a little harder to quantify, but another way of pointing it is really the strength of the signal, the hereditary persistence of fetal hemoglobin and its capacity to substantially mitigate the effect of sickle cell disease and thalassemia, were actually determined actually quite some time ago because this phenotypic change — this phenotype to genotype correlation was actually quite robust and identified actually a few decades ago, whereas the BC11A was identified really through a GWAS assessment, genome-wide assessment.

Operator: Thank you. We have reached the end of the Q&A session. And with that, ladies and gentlemen, this concludes today’s call. Thank you once again for your participation. You may now disconnect your lines.